Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: c29 peptide - UniQuest

Next Previous
X
Search
Drug Profile

Research programme: c29 peptide - UniQuest

Alternative Names: NeuroProtex - UniQuest

Latest Information Update: 13 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class Peptides
  • Mechanism of Action Apoptosis inhibitors; TrkA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 13 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in Australia (unspecified route)
  • 28 Sep 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Australia
  • 04 Aug 2016 Research programme: c29 peptide - UniQuest is available for licensing - http://uniquest.com.au/filething/get/11835/Neuroprotex%20c29%20Peptide%20UniQuest.pdf

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top